Company Overview
| Stock Name | Angelalign |
|---|---|
| Stock Code | 06699 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國領先的隱形矯治解決方案提供商,為牙科醫生提供自研的數字化正畸解決方案-時代天使隱形矯治系統,包括數字化輔助案例評估支持及矯治方案設計服務、定制可拆裝的隱形矯治器及雲服務平台iOrtho。 |
| Listing Date | 2021-06-16 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市 楊浦區 政立路500號 創智天地企業中心7號樓7樓 |
| Business Address (Hong Kong) | 香港 皇后大道東183號 合和中心54樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.angelalign.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 173.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 34,600 |
| Par Value | To be extracted |
| Offer Period | 2021-06-03 to 2021-06-08 |
| Global Offering Shares | 16,829,600 shares |
| HK Public Offer Shares (Initial) | 1,683,000 shares (10.0%) |
| Public Offer Lots (Initial) | 8,415lots (Pool A4,207lots,Pool B4,208lots) |
| International Placing Shares (Initial) | 15,146,600 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 165,807,100 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,911,520,800 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 34,600 |
| 5 lots | 1,000 | HK$ 173,000 |
| 10 lots | 2,000 | HK$ 346,000 |
| 15 lots | 3,000 | HK$ 519,000 |
| 20 lots | 4,000 | HK$ 692,000 |
| 25 lots | 5,000 | HK$ 865,000 |
| 30 lots | 6,000 | HK$ 1,038,000 |
| 35 lots | 7,000 | HK$ 1,211,000 |
| 40 lots | 8,000 | HK$ 1,384,000 |
| 45 lots | 9,000 | HK$ 1,557,000 |
| 50 lots | 10,000 | HK$ 1,730,000 |
| 75 lots | 15,000 | HK$ 2,595,000 |
| 100 lots | 20,000 | HK$ 3,460,000 |
| 102 lots | 20,461 | HK$ 3,539,753 |
| 125 lots | 25,000 | HK$ 4,325,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 150 lots | 30,000 | HK$ 5,190,000 |
| 150 lots | 30,099 | HK$ 5,207,127 |
| 175 lots | 35,000 | HK$ 6,055,000 |
| 192 lots | 38,571 | HK$ 6,672,783 |
| 200 lots | 40,000 | HK$ 6,920,000 |
| 225 lots | 45,000 | HK$ 7,785,000 |
| 250 lots | 50,000 | HK$ 8,650,000 |
| 300 lots | 60,000 | HK$ 10,380,000 |
| 350 lots | 70,000 | HK$ 12,110,000 |
| 400 lots | 80,000 | HK$ 13,840,000 |
| 450 lots | 90,000 | HK$ 15,570,000 |
| 500 lots | 100,000 | HK$ 17,300,000 |
| 750 lots | 150,000 | HK$ 25,950,000 |
| 1,000 lots | 200,000 | HK$ 34,600,000 |
| 1,250 lots | 250,000 | HK$ 43,250,000 |
| 1,500 lots | 300,000 | HK$ 51,900,000 |
| 1,750 lots | 350,000 | HK$ 60,550,000 |
| 2,000 lots | 400,000 | HK$ 69,200,000 |
| 2,250 lots | 450,000 | HK$ 77,850,000 |
| 2,500 lots | 500,000 | HK$ 86,500,000 |
| 3,000 lots | 600,000 | HK$ 103,800,000 |
| 3,500 lots | 700,000 | HK$ 121,100,000 |
| 4,000 lots | 800,000 | HK$ 138,400,000 |
| 4,207 lots | 841,400 | HK$ 145,562,200 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 13.53B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 26,529,136,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣150.9百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 179,736,000 |
| Listing Expenses / Funds Raised | ~6.17% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenue | 488,483 | 645,898 | 816,528 |
| Cost of sales | -176,765 | -228,756 | -241,479 |
| Gross profit | 311,718 | 417,142 | 575,049 |
| Other income and gains, net | 4,608 | 8,804 | 22,625 |
| Selling and distribution expenses | -81,439 | -122,645 | -148,835 |
| Administrative expenses | -107,702 | -136,544 | -154,423 |
| Operating profit | 75,271 | 84,191 | 187,885 |
| Net finance costs | -131 | 649 | 2,999 |
| Share of associates and JVs | -363 | -348 | 347 |
| Profit before tax | 74,777 | 84,492 | 191,231 |
| Income tax expense | -16,591 | -16,827 | -40,299 |
| Profit for the year | 58,186 | 67,665 | 150,932 |
| Profit attributable to owners | 59,758 | 68,837 | 150,689 |
Balance Sheet
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Cash and cash equivalents | 216,015 | 504,697 | 877,578 |
| Trade and bills receivables | 107,423 | 97,816 | 101,693 |
| Inventories | 21,663 | 22,827 | 19,914 |
| Total current assets | 372,813 | 655,575 | 1,003,708 |
| Total assets | 472,500 | 852,789 | 1,210,139 |
| Total current liabilities | 249,156 | 471,073 | 675,718 |
| Total liabilities | 308,948 | 559,410 | 712,465 |
| Total equity | 163,552 | 293,379 | 497,674 |
| Equity attributable to owners | 166,510 | 297,418 | 501,703 |
Cash Flow Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Net cash from operating activities | 144,585 | 402,332 | 408,279 |
| Net cash from investing activities | -2,062 | -103,035 | -7,276 |
| Net cash from financing activities | -61,827 | -11,304 | -23,333 |
| Net increase in cash | 80,696 | 287,993 | 377,670 |
| Purchase of PP&E | -35,938 | -39,779 | -41,285 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 401.0 |
|---|---|
| First Day Open | HK$ 400.0 |
| First Day Change | 131.79% |
| First Day Volume | 14863200.0 |
| First Day Turnover | 5878200000.0 |
| Use of Proceeds | 1、約39.9%用于為無錫市創美基地的建設提供資金;
2、約18.3%用于提升我們的研發能力以及為內部和合作研發項目提供資金;
3、約10.8%用于開發靈活及可擴展的智能信息技術系統以精簡及全面數字化我們運營的所有方面,并部署數據中間平臺;
4、約10.5%用于擴大我們的內部銷售團隊,并為銷售人員提供培訓課程以提高銷售效能和效率;
5、約9.6%用于為各種營銷及品牌推廣活動提供資金,以擴大用戶基礎并提升品牌形象;
6、約6.2%用于優化我們的醫學服務;
7、約4.7%用作營運資本及其他一般企業用途。 |
Underwriting Syndicate
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 馮岱 | — |
| Company Secretary | 朱凌波、朱卓婷 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 松柏正畸技術有限公司持股60.3110%、天榮企業有限公司持股14.2680%、廣福環球有限公司持股7.1388%(緊隨全球發售完成後) |
|---|




